Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

Afsaneh Shirani; Scott R. Dalton; Eric J. Avery; Lakshman Arcot Jayagopal; Christina Meyer; Olaf Stuve; Rana Zabad

doi:10.1177/11795735211053784

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

Afsaneh Shirani, Scott R. Dalton, Eric J. Avery, Lakshman Arcot Jayagopal, Christina Meyer, Olaf Stuve, Rana Zabad

Research output: Contribution to journal › Article › peer-review

Abstract

A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30⁺ lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA’s or Glatopa’s capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.

Original language	English (US)
Journal	Journal of Central Nervous System Disease
Volume	13
DOIs	https://doi.org/10.1177/11795735211053784
State	Published - 2021
Externally published	Yes

Keywords

Lymphomatoid papulosis
glatiramer acetate
glatiramoids
glatopa
multiple sclerosis
skin

ASJC Scopus subject areas

Clinical Neurology
Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1177/11795735211053784

Cite this

@article{918d3af8492546498ef82494be17504c,

title = "Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report",

abstract = "A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30+ lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA{\textquoteright}s or Glatopa{\textquoteright}s capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.",

keywords = "Lymphomatoid papulosis, glatiramer acetate, glatiramoids, glatopa, multiple sclerosis, skin",

author = "Afsaneh Shirani and Dalton, {Scott R.} and Avery, {Eric J.} and {Arcot Jayagopal}, Lakshman and Christina Meyer and Olaf Stuve and Rana Zabad",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2021.",

year = "2021",

doi = "10.1177/11795735211053784",

language = "English (US)",

volume = "13",

journal = "Journal of Central Nervous System Disease",

issn = "1179-5735",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis

T2 - A case report

AU - Shirani, Afsaneh

AU - Dalton, Scott R.

AU - Avery, Eric J.

AU - Arcot Jayagopal, Lakshman

AU - Meyer, Christina

AU - Stuve, Olaf

AU - Zabad, Rana

N1 - Publisher Copyright: © The Author(s) 2021.

PY - 2021

Y1 - 2021

N2 - A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30+ lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA’s or Glatopa’s capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.

AB - A 48-year-old Caucasian woman with history of multiple sclerosis (MS) presented with erythematous papulonodular lesions in her extremities and trunk. She was being treated with glatiramer acetate (GA) for the past 10 years and the glatiramoid, Glatopa, for 2 years prior to this presentation. A skin biopsy showed CD30+ lymphoproliferative disorder consistent with lymphomatoid papulosis (LyP). Three weeks after stopping Glatopa, her skin lesions were improved. It remains unclear whether GA’s or Glatopa’s capability to alter T-cell differentiation, may have a link with LyP. This case report is a reminder to be vigilant for skin lesions in patients with MS.

KW - Lymphomatoid papulosis

KW - glatiramer acetate

KW - glatiramoids

KW - glatopa

KW - multiple sclerosis

KW - skin

UR - http://www.scopus.com/inward/record.url?scp=85156154370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85156154370&partnerID=8YFLogxK

U2 - 10.1177/11795735211053784

DO - 10.1177/11795735211053784

M3 - Article

C2 - 34819759

AN - SCOPUS:85156154370

SN - 1179-5735

VL - 13

JO - Journal of Central Nervous System Disease

JF - Journal of Central Nervous System Disease

ER -

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this